San Diego's Endeavor BioMedicines has clinched a hefty $132.5M in Series C financing, spearheaded by AyurMaya and a lineup of heavyweight investors. This injection of funds will propel the clinical development of ENV-101, targeting fibrotic lung diseases, and ENV-501, a cutting-edge HER3-targeted antibody-drug conjugate for solid tumors. Led by visionary John Hood, Endeavor BioMedicines is on a mission to revolutionize patient care with groundbreaking treatments.